Why there is no approved BPC-157 dosage anywhere
If you are used to comparing providers, you already have a reasonable habit. Collect two or three quotes. Ask what is included. Check who is licensed. Pick whoever explains themselves best. That habit works because behind each provider sits a product with a fixed identity. Atorvastatin is atorvastatin at every pharmacy in the country, so the only variables left are service and price. The comparison you are being invited to make here breaks the habit, because the product itself has no fixed identity to compare.
BPC-157 is a synthetic pentadecapeptide based on a partial sequence of a protein found in gastric juice. It holds no marketing authorisation from the FDA, the EMA or the MHRA. It is sold as a research chemical rather than as a medicine.
An approved dose is not something a researcher notices and writes down. It is the output of a long administrative process. A sponsor runs escalating studies in humans, measures how much of the compound reaches the blood and how quickly it leaves, tests more than one amount against a comparator in the condition being treated, and hands the result to a regulator who decides which amount, by which route, in which population, for which condition, may be printed on a label. Only at the end of that does a dose exist as a regulated fact rather than an opinion.
None of that has been completed for this peptide. So there is no label. Because there is no label, there is no dose. Any figure offered to you is a figure somebody selected, not one anybody approved.
A dose is four things at once, not a single number
This is the part that price comparison quietly hides. A dose is never just a quantity. It is a quantity plus a route, plus a formulation, plus a defined population and condition. Change one of the four and the quantity stops meaning what it meant.
Give the same amount of a compound by mouth rather than by injection and the fraction reaching the bloodstream can change beyond recognition. Put the same amount in a different diluent, at a different concentration, into a person of a different size with different kidney function, and the exposure is no longer the same experiment. Regulated medicine deals with this by fixing all four variables and printing them together, which is why a prescribing document is several pages long rather than one line.
A number circulating on its own has not been stripped of that context. It never had it.
Where the circulating numbers actually came from
Every BPC-157 dosage in circulation traces back, with a little patience, to one of three sources.
The first is the animal literature. The efficacy work on this peptide is overwhelmingly rat and cell culture research, much of it produced by a small number of research groups, covering tendon, ligament, muscle and gut outcomes. Those rat studies do report amounts, because an experiment cannot run without one. But a rat dose is chosen for a rat experiment. Converting between species is an approximation pharmacologists use to pick a cautious starting point for a first human study, conducted under supervision with blood sampling and a stopping rule. It was never a method for producing a consumer instruction.
The second source is repetition. A figure appears on a forum, gets quoted in a sales page, then gets quoted back on the forum as though the sales page had confirmed it. After enough cycles it reads like consensus. Consensus about a number is not evidence for the number. It is evidence that people have been reading each other.
The third source is other providers. Clinics copy clinics. A protocol presented as house practice is often the same figure that was circulating years earlier, now on letterhead.
Does a consultation change the answer
This is worth being precise about, because a clinical setting genuinely adds some things and genuinely does not add others.
What a consultation can add is real and not trivial. Somebody takes a history. Somebody may notice that your shoulder needs imaging rather than a peptide. Somebody may decline to supply you at all, which is sometimes the most valuable thing a clinician does. A prescriber who knows your full medication list can flag an interaction risk that you would never have raised yourself.
What a consultation cannot add is the missing evidence. No clinician can examine you into the existence of a dose finding trial. What the professional setting does instead is transfer authority from the person to the product. The person may well have earned it. The product has not. That transfer is the specific thing to watch for in yourself when you are sitting in a calm room hearing a confident figure.
| What you are relying on | An approved prescription medicine | BPC-157 supplied as a research chemical |
|---|---|---|
| The amount | Set by human dose finding trials and printed on an approved label | Selected by the supplier or the provider |
| What is actually in the container | Verified batch by batch under an inspected manufacturing licence | Depends entirely on the seller's own testing, if any exists |
| The stated concentration | Held within a defined legal tolerance | Stated, but not guaranteed by anyone |
| Liability if it harms you | Sits with the manufacturer and the prescriber, with insurance behind both | Commonly pushed onto you by a research use disclaimer |
| Where a bad reaction goes | A national reporting system that can trigger an investigation | Nowhere that aggregates or acts |
| A wrong batch | A legal recall mechanism that can reach individual buyers | No mechanism at all |
| Interaction checking | A pharmacist working from your medication record | Only what you happen to mention in a consultation |
What the missing label costs you in practice
Read that table as a list of services rather than a list of rules, because that is what it is. Approval is expensive and slow, and the argument that it holds useful things back is not silly. But the fee you pay for regulated supply buys a set of specific protections, and stepping outside it means those protections are simply not purchased.
The most underrated of them is traceability. If an approved medicine turns out to have a contaminated batch, there is a chain that runs from the manufacturer to the pharmacy to your phone number. If a research chemical is contaminated, there is no chain. Nobody knows you bought it, nobody is obliged to find out, and the fact that you feel unwell three weeks later will never be connected to anything.
The second is what you can tell the next clinician. A surgeon, an oncologist or an emergency doctor can work with a drug name and a printed strength. They cannot work with a vial of unverified peptide of uncertain concentration from an unnamed source. Anything that cannot be described accurately cannot be accounted for in your care.
The trials that could eventually produce a number
Human research does exist, and pretending otherwise is as misleading as pretending the question is settled. Registered trials include NCT07803250, a Phase 1 trial of 30 participants in rotator cuff repair recovery that is not yet recruiting, and NCT02637284, a Phase 1 safety and pharmacokinetics study of 42 participants whose status is listed as unknown.
None of these has published efficacy results. Registration is a plan, not a finding. What matters for this page is what such trials are for: a Phase 1 pharmacokinetic study in humans is the machinery that turns a compound into a dose, because it measures actual exposure in actual people rather than inferring it from a rat. Until studies like these report, no honest source has a BPC-157 dosage to give you, and any source offering one confidently is telling you something about its own standards rather than about the peptide.
Related reading on this compound: [what is known about side effects](/blog/bpc-157-side-effects), [whether cycling applies here](/blog/bpc-157-cycle), [the benefit claims graded by organism](/blog/bpc-157-benefits).